SBIR Phase II:A novel peripheral nerve matrix platform for severe acute peripheral nerve injuries
Award amount
$996,171Program and phase
SBIR · Phase IIAward year
2022Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- RENERVA, INC.
- Proposal award date
- 2022-03-01
- Contract end date
- 2024-02-29
- UEI
- LJ97PLMMTGV1
- Solicitation number
- NSF 21-565
- Topic code
- BT
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PNM-CAP: A novel nerve cap to prevent painful neuroma formation in peripheral nerve injuries and amputations
- Restoration of Neuromuscular Function Following Critical Nerve Gap Injuries
- Restoration of Muscular Function Following Direct Muscle Neurotization
- Altering the injury microenvironment with a macrophage and Schwann Cell recruiting extracellular matrix-based hydrogel to improve laryngeal nerve injury recovery
- SBIR Phase I: Development of a Peripheral Nerve Matrix Conduit to Enable Nerve Regeneration
Research funding history
6 SBIR/STTR records share this UEI (2019–2025). Reported award amounts total $2,990,439. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation